Glatiramer

FDA Drug Profile — Glatiramer Acetate

Glatiramer is listed in the FDA National Drug Code directory with 3 NDC codes, marketed under brand name including Glatiramer Acetate. Available dosage forms: injection, solution, powder.

Drug details

Generic Name
Glatiramer
Brand Names
Glatiramer Acetate
Application Number
ANDA206936
Sponsor
Mylan Pharmaceuticals Inc.
NDC Codes
3
Dosage Forms
INJECTION, SOLUTION, POWDER
Routes
SUBCUTANEOUS
Active Ingredients
GLATIRAMER ACETATE, GLATIRAMER

Indications and Usage

1 INDICATIONS AND USAGE Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Glatiramer acetate injection is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 ).

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.